Palisade Bio (PALI) AI Stock Analysis

• Market Cap: $5.95M
• Dividend Yield: N/A
• Average Volume (3M): 710.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -100.00%
• EPS Growth: 53.88%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 4,795,646
• 10 Day Avg. Volume: 1,875,982
• 30 Day Avg. Volume: 710,716
• PEG Ratio: -0.08
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: -0.21
• Enterprise Value/Revenue: -28.50
• Enterprise Value/Gross Profit: -97.38
• Enterprise Value/Ebitda: 0.06
• 1Y Price Target: $2.00
• Price Target Upside: 83.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: ―

Palisade Bio's financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.

Positive Factors

Drug Development Strategy

The management's focus on developing PALI-2108 for fibrostenotic Crohn’s disease represents a strategic decision as there are currently no FDA approved therapies for this condition.

Drug Potency and Delivery

PALI-2108 has been found to be 20 times more potent than apremilast, thanks to its localized delivery to targeted tissue.

Negative Factors

Financing Concerns

Palisade Bio will require another financing following the data, which may be more dilutive given the current market dynamics.

Palisade Bio Business Overview & Revenue Model

Company Description

Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.

How the Company Makes Money

Palisade Bio makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its therapeutics to market, either independently or through strategic partnerships with larger pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, or milestone payments, which provide Palisade Bio with funding and shared resources. The company's revenue streams are heavily reliant on successful clinical trials, regulatory approvals, and the ability to effectively market its products to healthcare providers and patients. Additionally, Palisade Bio may secure funding through grants or investments to support its research and development efforts.

Palisade Bio Financial Statement Overview

Summary

Overall, Palisade Bio is struggling financially with consistent losses and negative cash flow. The balance sheet shows some stability due to low leverage, but the lack of revenue growth and profitability are significant concerns. The company heavily relies on external financing, which may not be sustainable long-term.

Income Statement

Palisade Bio shows no revenue growth and has been operating at a loss consistently. The gross profit margin is null due to no revenues, and the company faces a significant negative net profit margin, indicating poor profitability. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company has maintained a relatively low debt-to-equity ratio, suggesting conservative leverage. However, the equity ratio has been fluctuating, with a recent decline in stockholders' equity. Despite this, Palisade Bio maintains more equity than debt, providing some stability.

Cash Flow

Palisade Bio's cash flow situation is concerning with negative free cash flow and operating cash flow. The company has been relying on financing activities to cover its negative cash flows, which poses sustainability risks. The free cash flow to net income ratio is negative, indicating cash flow issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	250.00K	0.00	0.00	13.52K
Gross Profit	0.00	250.00K	-167.00K	-168.00K	-132.00K
EBITDA	-14.86M	-12.28M	-15.15M	-24.05M	-9.94M
Net Income	-14.44M	-12.30M	-14.26M	-26.62M	-10.32M
Balance Sheet
Total Assets	10.88M	14.05M	15.76M	12.51M	3.02M
Cash, Cash Equivalents and Short-Term Investments	9.82M	12.43M	12.38M	10.49M	713.00K
Total Debt	169.00K	369.00K	404.00K	199.00K	1.42M
Total Liabilities	3.39M	2.74M	3.28M	5.15M	19.62M
Stockholders Equity	7.49M	11.31M	12.48M	7.37M	-16.60M
Cash Flow
Free Cash Flow	-12.19M	-11.14M	-13.37M	-14.77M	-4.77M
Operating Cash Flow	-12.19M	-11.13M	-13.36M	-14.77M	-4.77M
Investing Cash Flow	0.00	-4.00K	-10.00K	-54.00K	-6.00K
Financing Cash Flow	9.58M	11.19M	15.26M	24.61M	1.89M

Palisade Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PALI, the sentiment is Positive. The current price of 1.09 is above the 20-day moving average (MA) of 0.86, above the 50-day MA of 0.77, and below the 200-day MA of 1.40, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 61.78 is Neutral, neither overbought nor oversold. The STOCH value of 66.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PALI.

Palisade Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	HK$17.39B	5.61	-7.44%	3.56%	11.55%	-28.15%
PALI	45 Neutral	$5.95M	―	-170.72%	―	-100.00%	53.88%
ARTL	34 Underperform	$9.81M	―	-190.70%	―	―	14.28%
GLTO	29 Underperform	$4.99M	―	-91.32%	―	―	48.81%
GLMD	28 Underperform	$4.31M	―	-49.58%	―	―	71.41%
QNRX	25 Underperform	$4.80M	―	-138.80%	―	―	42.26%